Mexican Concensus of Multiple Myeloma.

Area of Science:

• Hematology
• Oncology
• Medical Diagnostics

Background:

• Multiple myeloma (MM) is a common hematologic malignancy characterized by the CRAB criteria (hypercalcemia, renal failure, anemia, lytic bone lesions).
• Renal failure is a frequent complication, necessitating accurate diagnostic methods.
• Recent advancements include new biomarkers for MM diagnosis, such as clonal plasma cells, light chain ratios, and MRI findings.

Framework:

• This consensus integrates Mexican specialists to update diagnostic and therapeutic strategies for multiple myeloma.
• It emphasizes the importance of differential diagnosis, including plasma cell leukemia and plasmacytomas.
• The framework highlights the evolution of MM treatment from early chemotherapy to modern targeted therapies.

Implementation:

• Early MM detection utilizes established CRAB criteria and novel biomarkers.
• Therapeutic strategies have evolved from single-agent melphalan to combination regimens.
• Introduction of proteasome inhibitors (e.g., bortezomib) and immunomodulators (e.g., thalidomide, lenalidomide) has revolutionized MM management.

Implications:

• Improved diagnostic accuracy leads to earlier intervention for multiple myeloma.
• Novel therapeutic agents have resulted in deeper responses, prolonged remissions, and enhanced patient quality of life.
• This collaborative effort aims to disseminate updated knowledge for better MM patient care in Mexico.